Edition:
United States

Biotec Pharmacon ASA (BIOTEC.OL)

BIOTEC.OL on Oslo Stock Exchange

11.55NOK
20 Jan 2017
Change (% chg)

kr0.15 (+1.32%)
Prev Close
kr11.40
Open
kr11.60
Day's High
kr11.70
Day's Low
kr11.35
Volume
14,107
Avg. Vol
93,281
52-wk High
kr13.60
52-wk Low
kr10.00

BIOTEC.OL

Chart for BIOTEC.OL

About

Biotec Pharmacon ASA is a Norway-based biopharmaceutical company that develops, manufactures and markets immune modulating compounds for the human health sectors and marine enzymes used in molecular biology. The Company focuses on new solutions within wound care, cancer therapies and other immune related disease areas. It has a... (more)

Overall

Beta: -0.55
Market Cap(Mil.): kr507.56
Shares Outstanding(Mil.): 43.94
Dividend: --
Yield (%): --

Financials

  BIOTEC.OL Industry Sector
P/E (TTM): -- 29.51 30.38
EPS (TTM): -0.46 -- --
ROI: -23.99 15.44 14.86
ROE: -23.99 16.62 16.28

BRIEF-Biotec Pharmacon EBITDA loss widens to NOK 5.9 million

* Q3 revenue 21.1 million Norwegian crowns ($2.5 million) versus 16.4 million crowns year ago

Oct 26 2016

BRIEF-Biotec Pharmacon signs supply agreement in Germany

* Signs supply agreement for Woulgan with first homecare provider in Germany

Oct 24 2016

BRIEF-Biotec Pharmacon: Arcticzymes launches polymerase product, gets patent in US

* Says subsidiary ArcticZymes has launched its first DNA polymerase product onto market

Sep 30 2016

BRIEF-Biotec Pharmacon confirms reimbursement in another region in Germany

* Receives confirmation of Woulgan being reimbursed by Statutory Health Insurance fund (krankenkasse) in another region in Germeny

Sep 19 2016

BRIEF-Biotec Pharmacon Q2 EBITDA loss widens to NOK 1.6 mln

* Q2 revenue 15.3 million Norwegian crowns ($1.86 million) versus 11.5 million crowns year ago

Aug 17 2016

Earnings vs. Estimates